Neulasta (pegfilgrastim), a new long-acting form of Neupogen (filgrastim)
April 2002
Amgen will soon launch Neulasta (pegfilgrastim), a new long-acting form of Neupogen (filgrastim).
It's a new option for preventing infection in chemo patients. Neulasta and Neupogen stimulate the production of white blood cells.
Neulasta is made by attaching polyethylene glycol (PEG) to filgrastim. The "pegylated" version is cleared more slowly so it can be given less often.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote